Metabonomics in Pharmaceutical Discovery and Development

Citations Over TimeTop 10% of 2006 papers

Abstract

Metabonomics has emerged as a key technology in pharmaceutical discovery and development, evolving as the small molecule counterpart of transcriptomics and proteomics. In drug discovery laboratories, metabonomics aids in target identification, phenotyping, and the understanding of the biochemical basis of disease and toxicity. This review focuses on three areas where metabonomics is used in the industry: (1) analytical considerations, (2) chemometric and statistical concerns, and (3) biological aspects and applications.

Related Papers

• → Keynote review: Structural biology and drug discovery(2005)336 cited
• → The use of constitutively active GPCRs in drug discovery and functional genomics(2002)109 cited
• → Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery(2007)34 cited
• → Functional cell-based uHTS in chemical genomic drug discovery(2002)56 cited
• → Using model-system genetics for drug-based target discovery(2001)32 cited